Clinical Trials Browser

NIH × Myeloproliferative Disorders × Idarubicin × Clear all

NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

50 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT00005823 2013-12-18

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3 Completed

2,000 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00331513 2013-09-30

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Phase 1 Completed

40 enrolled

LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma